Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
02 June 1995Website:
http://www.resmed.comNext earnings report:
02 August 2024Last dividends:
08 May 2024Next dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:01:00 GMTAnalysts recommendations
Institutional Ownership
Included in screeners
RMD Latest News
ResMed is potentially undervalued, trading at a 31.65% discount from its 5Y average P/E ratio, with strong market leadership and untapped growth potential in OSA treatment. Projected 10-year EPS growth at 12.5% annually with a P/E of 25 gives a 2034 price target of $529.25 and an implied 10.9% CAGR, with potential for higher returns. Risks include competitive pressures from Philips' market re-entry, technological advances reducing OSA prevalence, and challenges in increasing diagnosis rates, yet ResMed's strong market position supports long-term investment.
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, August 1, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Shares of ResMed, a maker of CPAP and other sleep-apnea airway machines, have dropped because of weight-loss developments. It's an overreaction.
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday.
Shares of medical device maker ResMed (RMD) are tumbling in intraday trading Monday as markets react to a pair of Phase 3 clinical trials from drugmaker Eli Lilly (LLY) released Friday that could have an impact on ResMed's future business.
Eli Lilly is seeking FDA approval to expand the uses for its weight-loss drug Zepbound to include sleep apnea.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. Held in Houston, the event brought together scientific and medical experts focused on sleep health.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA) Prevalence of OSA in the United States expected to increase 26.7% in men and women aged 30 –70 Real-world trends of glucagon-like peptide-1 (GLP-1) receptor agonist and PAP therapy use show patients who were adherent to their GLP-1 medication had higher levels of PAP therapy use than those who were non-adherent to their GLP-1 medication SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- A number of accomplished medical and scientific experts presented critical new research on sleep conditions and their effect on cardiovascular health at the American Thoracic Society International Conference. The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits.
What type of business is ResMed?
ResMed Inc. is one of the world leaders in the development, manufacturing, and marketing of medical devices and cloud software solutions for the diagnosis, treatment, and management of respiratory disorders. The company's portfolio includes a range of innovative products for a wide spectrum of respiratory diseases, including technologies used in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in hospitals and homes, headgear and other accessories, dental devices, portable oxygen concentrators, as well as cloud software information solutions for managing patient outcomes and business processes for clients and suppliers. ResMed Inc. was founded in 1989 with headquarters in San Diego, California.
What sector is ResMed in?
ResMed is in the Healthcare sector
What industry is ResMed in?
ResMed is in the Medical Instruments & Supplies industry
What country is ResMed from?
ResMed is headquartered in United States
When did ResMed go public?
ResMed initial public offering (IPO) was on 02 June 1995
What is ResMed website?
https://www.resmed.com
Is ResMed in the S&P 500?
Yes, ResMed is included in the S&P 500 index
Is ResMed in the NASDAQ 100?
No, ResMed is not included in the NASDAQ 100 index
Is ResMed in the Dow Jones?
No, ResMed is not included in the Dow Jones index
When does ResMed report earnings?
The next expected earnings date for ResMed is 02 August 2024